Reconciling Genomic Ambiguity and Clinical Certainty in Refractory Panniculitis — Case Report

Article availability and source metadata

The material supplied consisted of Frontiers in Immunology website navigation and metadata links; the actual article text for the case report titled "Reconciling genomic ambiguity with clinical certainty in refractory panniculitis" was not included in the provided source. The article is identified by the journal Frontiers in Immunology and the DOI referenced in the URL path (10.3389/fimmu.2026.1906895), but the body text, figures, tables, and case-level details were not present in the content we received.

The source content did list the journal's topical sections (for example, inflammation, autoinflammatory disorders, microbial immunology, and related areas), which indicate the journal's scope and possible contextual placement of the case report. However, those listings are site navigation elements and do not substitute for the article's clinical content or data.

Limits of supplied content and missing clinical data

The provided source did not include any of the following items that are essential for clinical appraisal:

• Patient demographics and clinical presentation.
• Physical examination findings and laboratory results.
• Histopathology or imaging reports.
• Genomic testing methods, bioinformatic analyses, variant calls, or variant interpretation.
• Diagnostic reasoning reconciling genomic findings with clinical assessment.
• Specific therapies tried, dosing, duration, or response data.
• Adverse events, clinical course, and final outcomes.
• Authors' discussion, limitations, or explicit conclusions.

Because these elements were not reported in the supplied content, it is impossible to summarize or evaluate the case report's clinical messages, strength of evidence, or applicability to practice from the material available here.

Title-based interpretation: likely clinical focus and themes

The article title suggests the report centers on a case of refractory panniculitis in which genomic testing produced ambiguous or uncertain results, and clinicians sought to reconcile those genomic data with clinical judgment to reach a management decision. This interpretation is an inference from the title alone and is not a substitute for the article text. Key concepts implied by the title include:

• A dermatologic or subcutaneous inflammatory condition resistant to standard therapies (refractory panniculitis).
• Use of genomic analysis (for example, germline or somatic sequencing, gene panels, or broader genomic approaches) that produced results difficult to interpret definitively (genomic ambiguity).
• Emphasis on clinical reasoning and decision-making when molecular data are inconclusive (clinical certainty despite genomic uncertainty).

These thematic elements may reflect topics commonly discussed in case reports that link genomics and clinical care, such as variant interpretation, phenotype–genotype correlation, multidisciplinary consultation, and therapeutic decision-making when molecular diagnostics do not yield a clear causal diagnosis. However, specific methods, variants, or management strategies were not provided in the source and therefore are not reported here.

Where to obtain the full article and recommended next steps

To access the complete case report and all clinical and genomic details, retrieve the full text from Frontiers in Immunology using the provided DOI/URL (the article identifier appears in the source). For clinicians and researchers who need to apply or evaluate the case, obtaining the full article is necessary to review:

• Exact patient history, examination, and diagnostic studies.
• Genomic testing approach, variant-level data, and interpretation framework.
• Treatment interventions tried, rationale for therapy selection, and outcomes.
• Authors' discussion of the interplay between molecular ambiguity and clinical judgment.

If you would like, I can:

• Attempt to fetch and summarize the full article text if you provide access or paste the article body here.
• Provide a checklist of specific data elements to look for in the full report (for example, sequencing platform, variant allele fraction, ACMG classification, histopathology features, treatment timeline) to support critical appraisal.

Note: The current rewrite does not invent or assume specific clinical facts beyond cautious interpretation of the article title; all case-level details were not reported in the supplied source material and thus are not included here.